Bluejay Diagnostics (BJDX) Net Margin (2022)
Bluejay Diagnostics' (BJDX) quarterly Net Margin came in at 797.35% in Q2 2022.
Bluejay Diagnostics (BJDX) Net Margin (2022) Analysis & Trends
Bluejay Diagnostics has disclosed Net Margin across 1 years of filings, most recently posting 797.35% for Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 12.75% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.00% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 16.74% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 8.01% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Bluejay Diagnostics | 4.43 Mn | 746,549.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -797.35% |